IGC
$0.29
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia.
Recent News
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
IGC Pharma expands Phase 2 CALMA trial with new clinical site
IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease dementia. VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized patient populations while maintaining continuity of clinical care. IGC Pharma believes this practice-integrated mo
Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says
Cannabis stocks jumped on Friday following reports that President Donald Trump will significantly ease federal restrictions on marijuana, with an executive order seen as coming as soon as Monday, CNBC’s Alex Harring and Brandon Gomez report. Trump is expected to use an executive order to instruct federal agencies to reclassify marijuana as a less regulated Schedule III drug from a Schedule I, the Washington Post reported on Thursday. Such a move would allow cannabis companies to fall under diffe
IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers
IGC Pharma Inc (IGC) showcases progress in Alzheimer's research, financial strategies, and operational efficiencies amid regulatory challenges.
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?